Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New technology could help AIDS researchers develop new vaccines

By Drug Discovery Trends Editor | October 17, 2011

MIT T Cells

Inside these squares, single T cells taken from HIV-infected patients interact with infected cells. This technology, developed by MIT chemical engineers, offers the first way to study how effectively individual T cells respond to HIV-infected cells. Image: Navin Varadarajan

One of the obstacles
to developing an effective AIDS vaccine is the difficulty in measuring how well
a potential vaccine primes the body to defend itself against HIV.

Ideally, scientists
would like their vaccines to provoke T cells, a critical component of the
immune response, to recognize and kill HIV-infected cells. Unfortunately, there
is no fast and easy way to monitor whether T cells are actually doing that.
Instead, researchers measure the amount of a protein called interferon gamma
that T cells secrete when they encounter an infected cell. Studies have shown,
however, that this “surrogate” measurement doesn’t necessarily predict a T
cell’s ability to kill HIV-infected cells.

In an advance that
could overcome that obstacle, a team of researchers at the Massachusetts
Institute of Technology (MIT) has developed a new technology that can measure
multiple aspects of individual T cells’ responses to HIV-infected cells,
including their ability to kill them. The technology could make it easier to
monitor and design vaccines against HIV, says J. Christopher Love, the Latham
Family Career Development Associate Professor of Chemical Engineering and
leader of the research team.

The technology, described in a paper published in the Journal of
Clinical Investigation
, involves two steps. First, the researchers place
single T cells taken from HIV-infected patients into tiny wells on a plate, where
they are exposed to HIV-infected cells. The researchers can detect whether the
T cells kill the infected cells with probes that glow when the dying cells’
nuclei become compromised.

Next, the researchers
measure interferon gamma production with a microengraving technique they
developed in 2008
. Secretions from each cell are imprinted on a glass
slide, which can then be tested for the presence of specific proteins. Because
each cell has its own “address” on the slide, the secretions can be traced back
to individual cells, and their interferon gamma production can be correlated
directly to their cell-killing ability.

The same technology
could be adapted to measure cells’ output of any other immune system protein.

In this study, the
researchers found that while the percentage of T cells that secrete interferon
gamma is similar to the percentage of those that kill infected cells, the
populations are not identical. In future studies, the researchers hope to find
markers that do correlate with cell-killing ability, making it easier to
evaluate a potential vaccine’s effectiveness.

“Now that we have a
tool to look directly at a variety of different functional activities, you can
go in and start to evaluate other markers that may be better predictors of
killing. Those then become what you would want to monitor in vaccine trials,”
says Love, who is also a member of the Ragon Institute of MGH, MIT and Harvard
and the David H. Koch Institute for Integrative Cancer Research at MIT.

“The appeal of this
technology is that it can help us understand more about what’s going on in
single cells,” says Alan Landay, professor of immunology and microbiology at Rush Medical
College. “It helps us
rethink what we understand about immunology and immune function.”

More research will be
needed to develop the technology to the point where it can be used routinely in
vaccine trials for large-scale studies of patient samples.

SOURCE


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE